Home Wellness Insights

27Jul

Sleep Apnea Statistics 2026 | Prevalence, Costs & Zepbound® OSA Data

Sleep Apnea Statistics 2026: Prevalence, Undiagnosed Cases, Economic Cost & GLP-1 Treatment Data | GoalBMI Wellness

📊 Statistics Report — Updated July 2026

Sleep Apnea Statistics 2026: Prevalence, Undiagnosed Cases, Economic Cost & GLP-1 Treatment Data

The most comprehensive obstructive sleep apnea statistics resource for 2026. Covers US prevalence estimates, the 80% undiagnosed gap, $150 billion economic burden, the obesity connection, SURMOUNT-OSA trial results, and how Zepbound became the first medication ever approved for OSA.

📅 Last Updated: July 2026 ⏱ 14 min read ✔ Physician Reviewed 📚 12 Cited Sources

80.6M

US adults estimated to have OSA — 32.2% of adults 20+

SLEEP / Oxford Academic, 2025

80%

Of all OSA cases remain undiagnosed — roughly 68.5 million people

SLEEP / AASM, 2025

$150B

Annual US economic cost of undiagnosed sleep apnea

AASM / Frost & Sullivan

62.8%

Reduction in OSA severity with tirzepatide vs placebo

SURMOUNT-OSA, NEJM 2024

Obstructive sleep apnea is one of the most common chronic conditions in America — and one of the least recognised. An estimated 80 million US adults have it, roughly four in five do not know, and untreated cases cost the economy around $150 billion every year. December 2024 marked a genuine turning point: for the first time in medical history, the FDA approved a medication to treat it. This page compiles what the current data actually shows.

Section 01

How Many Americans Actually Have Sleep Apnea — And How Many Know It

Estimates vary depending on the diagnostic criteria used, but every recent analysis points in the same direction: obstructive sleep apnea is far more widespread than most people, and many clinicians, assume.

80.6M

US adults with OSA in 2024 — 32.2% of adults aged 20 and older

85.6M

Upper-bound estimate using prevalence ranges of 24–33%

~1B

People affected by sleep apnea worldwide

OSA Prevalence in US Adults by Sex (%, adults aged 20+)

Source: SLEEP / Oxford Academic, 2025. Adjusted for obesity as a major risk factor. Men are affected at roughly 1.5× the rate of women.

📊

Most Cases Are Mild — But Moderate-to-Severe Still Means Millions

Severity distribution across US OSA cases is approximately 61% mild, 24% moderate, and 15% severe by one 2025 estimate, or 52% mild, 30% moderate, 18% severe by another. Even at the conservative end, that places roughly 31 million Americans in the moderate-to-severe range — the population for whom treatment is most clearly indicated and for whom Zepbound® is now FDA-approved. (Source: SLEEP, Oxford Academic, 2025)

😴

94% of People With OSA Snore — But Snoring Alone Proves Nothing

While 94% of people with obstructive sleep apnea snore, the reverse is not true — most people who snore do not have OSA. Snoring is a signal worth investigating, not a diagnosis. Confirming OSA requires a sleep study, either in a lab or through an approved home sleep apnea test ordered by a physician.

Section 02

The 80% Problem — Why Most Cases Never Reach a Diagnosis

The single most striking statistic in sleep medicine is not prevalence — it is how few people with the condition are ever identified. And the gaps continue even after diagnosis.

68.5M

Americans with undiagnosed OSA — 80% of all cases

17.1M

Diagnosed — roughly 1 in 5 of everyone affected

4.5M

Diagnosed but still untreated — 26% of the diagnosed group

10.8M

Started PAP therapy then stopped or failed adherence criteria

The treatment funnel is leaky at every stage. Of an estimated 85.6 million adults with OSA, roughly 68.5 million (80%) are undiagnosed. Among the ~17.1 million who are diagnosed, 4.5 million (26%) remain untreated. And of those who do start PAP therapy, more than half — 63%, around 10.8 million people — discontinue treatment or fail to meet adherence criteria. Only an estimated 9 to 12.5 million adults are both diagnosed and actively treated. (Source: SLEEP / Oxford Academic, 2025)

The US Sleep Apnea Treatment Funnel — From Prevalence to Active Treatment (Millions)

Source: SLEEP / Oxford Academic, 2025, using AASM 2016 burden data and real-world claims analyses. Each stage loses a substantial share of patients.

🚗

Undiagnosed OSA Has Consequences Beyond the Bedroom

Untreated sleep apnea is associated with hypertension, type 2 diabetes, depression, and stroke — and with significant public safety costs. The National Safety Council attributed 810,000 motor vehicle collisions and 1,400 fatalities in the United States to sleep apnea in a single year. Untreated OSA patients incur healthcare costs averaging $19,566 per year, driven primarily by inpatient care. (Source: Sleep Science / NIH PMC)

Section 03

$150 Billion a Year — Counting the Cost of Leaving It Untreated

The American Academy of Sleep Medicine commissioned Frost & Sullivan to quantify what undiagnosed sleep apnea costs the United States annually. The breakdown reveals how much of the burden sits outside the healthcare system entirely.

Annual US Economic Cost of Undiagnosed Sleep Apnea — $150 Billion Breakdown

Source: AASM / Frost & Sullivan analysis. Lost productivity accounts for the majority of total cost.

Cost Category	Annual Amount	Share of Total
Lost workplace productivity	$86.9 billion	58%
Increased healthcare utilization	$30.0 billion	20%
Motor vehicle crashes	$26.2 billion	17%
Workplace injuries	$6.5 billion	4%
Total annual burden	~$150 billion	100%

For scale: The estimated total cost of sleep disorders in the United States is comparable in magnitude to the cost of diabetes — around $130–150 billion per year. Yet unlike diabetes, the overwhelming majority of cases have never been identified, which means the true figure is almost certainly an underestimate.

💼

Treatment Produces Measurable Return

In an AASM survey of 506 patients currently being treated for OSA, respondents reported a 40% decline in workplace absences after starting treatment, alongside better sleep and greater productivity. Approximately 78% of patients said sleep apnea treatment was a good investment. (Source: AASM / Frost & Sullivan)

Section 04

What the BMI Data Reveals About Weight and Airway Collapse

Obesity is the single most modifiable risk factor for obstructive sleep apnea. But the relationship is more nuanced than “obesity causes sleep apnea” — and understanding that nuance matters clinically.

4.84×

Higher odds of OSA with obesity (BMI ≥30) vs BMI under 25

2.18×

Higher odds of OSA with overweight (BMI 25–30) vs BMI under 25

74.3%

Of individuals with obesity have some degree of OSA

Odds of Obstructive Sleep Apnea by BMI Category (vs BMI < 25)

Source: Individual participant data meta-analysis of 12,860 adults across four community-based cohorts, NIH PMC 2025.

An important corrective: A 2025 meta-analysis of 12,860 adults found that most adults with OSA do not have obesity — 44.4% have overweight status and 23.5% have normal weight or are underweight. Only about 31.5% of people with OSA have obesity. Sleep apnea is strongly associated with excess weight, but it is not exclusive to it. Anatomical factors, age, and sex all contribute independently. (Source: NIH PMC meta-analysis, 2025)

⚖️

60% of Moderate-to-Severe Cases Are Attributable to Obesity

While most OSA cases overall are not in people with obesity, the picture changes at higher severity. Approximately 60% of moderate-to-severe OSA cases are attributable to obesity, and an estimated 41–70% of US patients with OSA have obesity. This is precisely why weight-based treatment has the strongest evidence in the moderate-to-severe population — and why the FDA approval for Zepbound® was specifically limited to adults with obesity. (Source: ResMed clinical FAQ, 2026)

Section 05

December 2024 — The Month Sleep Apnea Treatment Changed

On December 20, 2024, the FDA approved Zepbound® (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity. It was the first pharmaceutical treatment ever approved for the condition — after decades in which the only options were mechanical or surgical.

What was actually approved: Zepbound® is indicated for moderate-to-severe OSA in adults with obesity (BMI ≥30), in combination with a reduced-calorie diet and increased physical activity. It is not approved for mild OSA, and it is not approved for patients with OSA who do not have obesity. Approval was based on the SURMOUNT-OSA phase 3 program. (Source: FDA press announcement, December 20, 2024)

SURMOUNT-OSA — What the Trials Measured

The SURMOUNT-OSA program comprised two parallel phase 3 trials, both using change in the apnea-hypopnea index (AHI) from baseline as the primary endpoint. AHI counts breathing interruptions per hour of sleep.

Trial Design Element	Detail
Trial 1	n=234 — participants unable or unwilling to use PAP therapy
Trial 2	Participants already receiving PAP therapy at baseline
Population	Moderate-to-severe OSA (AHI ≥15 events/hour) with obesity (BMI ≥30), without type 1 or type 2 diabetes
Dosing	Tirzepatide maximum tolerated dose (10mg or 15mg) vs placebo
Primary endpoint	Change in apnea-hypopnea index (AHI) from baseline
Headline result	Up to 62.8% reduction in AHI vs placebo — P<0.001 for superiority
Publication	Malhotra A, et al. NEJM 2024;391(13):1193–1205

📉

Real-World Data Points the Same Direction

A retrospective claims analysis found that patients on anti-obesity medications had an OSA incidence of 3.12% versus 12.56% in the non-medicated cohort — a 40% lower likelihood of developing OSA after adjustment (hazard ratio 0.60, p<0.0001). Tirzepatide users showed slightly lower OSA incidence than semaglutide users (2.65% vs 3.18%), though the difference did not reach statistical significance after adjustment. (Source: Medical Research Archives, January 2025)

📖 Related Programs at GoalBMI Wellness

Tirzepatide Programs — Zepbound® & Mounjaro® Tirzepatide Statistics 2026 Medical Weight Loss Programs Type 2 Diabetes Statistics 2026

Section 06

Where CPAP Still Wins — And Where Medication Fits Alongside It

The arrival of a drug treatment has not displaced positive airway pressure therapy. Understanding what each does — and does not do — matters for anyone weighing options.

Medication is not a CPAP replacement. ResMed’s clinical position, echoed by sleep medicine specialists, is direct: “CPAP remains the gold standard for any patient with moderate-to-severe OSA and provides immediate relief from the onset of treatment.” Weight management is complementary to PAP therapy, not a substitute for it. Any decision to change or stop PAP therapy belongs with your sleep physician. (Source: ResMed, 2026)

Immediate

CPAP works from the first night of use — no waiting period

63%

Of PAP starters discontinue or fail to meet adherence criteria

🤝

GLP-1 Use Is Associated With Higher CPAP Initiation, Not Lower

A ResMed analysis of real-world IQVIA data found that patients with an OSA diagnosis who filled a GLP-1 prescription were 10.8 percentage points more likely to initiate CPAP therapy than those who did not. Rather than replacing PAP therapy, GLP-1 treatment appears to coincide with greater engagement in OSA care overall — likely reflecting patients who are actively addressing their health across multiple fronts.

📋

What Patients Told Researchers About Their Preferences

The PRO-CON OSA survey, conducted from November 2024 to August 2025 across US patients and 114 sleep medicine providers, found that among patient respondents: 73% had attempted weight loss three or more times, 77% had used CPAP, and 21% had used GLP-1 receptor agonists such as tirzepatide. Most reported at least one comorbidity such as hypertension alongside frequent sleepiness, fatigue, or unrefreshing sleep. (Source: PRO-CON OSA Survey, UCSD, 2025)

Where the Numbers Stand — Key Sleep Apnea Metrics

US adults with OSA (32.2% of adults 20+)32.2%

OSA cases that remain undiagnosed80%

PAP therapy starters who discontinue or fail adherence63%

Individuals with obesity who have some degree of OSA74.3%

Reduction in AHI with tirzepatide vs placebo (SURMOUNT-OSA)62.8%

Lower likelihood of OSA on anti-obesity medication40%

Section 07

Projecting Forward to 2050 — What the Modelling Studies Predict

A prospective modelling study published in The Lancet Respiratory Medicine in August 2025 projected the 30-year trajectory of obstructive sleep apnea in the United States, factoring in population age, sex, and BMI distribution changes.

76.6M

Projected US OSA cases by 2050 (AHI ≥5/h)

46.2%

Projected 2050 prevalence — up from 34.3%

+34.7%

Relative increase in OSA prevalence over three decades

Women are projected to see the steeper rise. The model predicts a 65.4% relative increase in OSA prevalence among females — from 22.8% to 37.7%, reaching 30.4 million cases — versus a more moderate 19.3% relative increase among males, from 45.6% to 54.4%, reaching 45.9 million cases. Notably, the model explicitly incorporates the introduction of GLP-1 therapy into its projections. (Source: Lancet Respiratory Medicine, August 2025)

🔬

More OSA Drug Trials Are Now Underway

Zepbound® is unlikely to remain the only option for long. The ATTAIN-OSA phase 3 trial is currently evaluating orforglipron — an oral GLP-1 — for moderate-to-severe obstructive sleep apnea in adults with obesity or overweight. Study design and baseline characteristics were published in Contemporary Clinical Trials Communications in 2026. The therapeutic landscape for OSA is likely to look materially different within a few years.

Section 08

From CPAP to Pharmacotherapy — A Treatment Timeline

1981

CPAP Introduced — The First Effective OSA Treatment

Continuous positive airway pressure therapy is developed, transforming sleep apnea from an essentially untreatable condition into a manageable one. It remains the gold standard for moderate-to-severe OSA more than four decades later.

2016

AASM Quantifies the National Burden

The American Academy of Sleep Medicine commissions Frost & Sullivan to assess the clinical and economic burden of OSA in the US. The resulting analysis estimates undiagnosed sleep apnea costs the country approximately $150 billion annually — with lost productivity accounting for the majority.

June 2024

SURMOUNT-OSA Results Published in NEJM

Malhotra and colleagues publish the SURMOUNT-OSA phase 3 results in the New England Journal of Medicine, reporting up to a 62.8% reduction in apnea-hypopnea index with tirzepatide versus placebo in adults with moderate-to-severe OSA and obesity. Two parallel trials assess patients both on and off PAP therapy.

December 20, 2024

FDA Approves the First Medication Ever for Sleep Apnea

The FDA approves Zepbound® (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity. It is the first pharmaceutical treatment approved for OSA in history. The American Academy of Sleep Medicine issues a statement on the approval.

August 2025

30-Year Burden Projection Published

The Lancet Respiratory Medicine publishes a prospective modelling study projecting US OSA prevalence rising to 46.2% by 2050 — 76.6 million cases — with women experiencing a substantially steeper relative increase than men. The model incorporates the introduction of GLP-1 therapy.

2026

Oral GLP-1 Enters OSA Trials

The ATTAIN-OSA phase 3 trial begins evaluating orforglipron, an oral GLP-1, for moderate-to-severe OSA in adults with obesity or overweight. Meanwhile the American Academy of Sleep Medicine publishes updated provider guidance on Zepbound® for OSA.

Tirzepatide Programs

Accessing Physician-Supervised Tirzepatide for Obesity and OSA

GoalBMI Wellness provides physician-supervised tirzepatide programs via telehealth for eligible patients. If you have been diagnosed with moderate-to-severe obstructive sleep apnea and have obesity, Zepbound® may be clinically appropriate — a licensed provider will assess this during your evaluation.

GoalBMI Wellness tirzepatide program pricing — Zepbound and Mounjaro for obesity and sleep apnea patients

Before you start: A sleep apnea diagnosis requires a sleep study — either an in-lab polysomnogram or an approved home sleep apnea test ordered by a physician. If you suspect you have OSA but have never been tested, testing is the first step, not medication. If you are already using CPAP, do not stop or reduce it without discussing it with your sleep physician first.

Book a Consultation → Verify Insurance →

Programs available via telehealth across New York, New Jersey, and Pennsylvania.

Real Patient Outcomes

Before & After — Weight Reduction in Supervised Tirzepatide Programs

These results are from real GoalBMI Wellness patients in physician-supervised GLP-1 programs. In SURMOUNT-OSA, improvements in apnea-hypopnea index tracked alongside weight reduction — which is the mechanism by which tirzepatide affects sleep apnea severity.

Before and after tirzepatide weight loss results — GoalBMI Wellness patients with obesity

See more patient before & after results →

Results disclaimer: Individual results may vary. Photos represent real patients from physician-supervised GoalBMI Wellness programs shared with patient consent. These images depict weight loss outcomes and are not a representation of sleep apnea treatment results. Results depend on individual health factors, program adherence, and clinical evaluation.

Section 09

Questions Patients Ask About Sleep Apnea and GLP-1 Treatment

Estimates range from 80.6 million to 85.6 million US adults, representing roughly 32% of adults aged 20 and older. Prevalence is substantially higher in men (39%) than women (25.8%). Severity distribution is approximately 61% mild, 24% moderate, and 15% severe — meaning around 31 million Americans fall in the moderate-to-severe range where treatment is most clearly indicated. Worldwide, close to 1 billion people are affected.

Sleep apnea occurs during sleep, so most people are unaware of their own symptoms — a bed partner often notices first. Symptoms like daytime fatigue and unrefreshing sleep are easily attributed to stress, ageing, or busy schedules. Diagnosis requires a sleep study, which historically meant an overnight lab visit. Roughly 68.5 million Americans have undiagnosed OSA, and even among those diagnosed, 26% remain untreated and 63% of PAP starters discontinue or fail adherence criteria.

Yes. On December 20, 2024, the FDA approved Zepbound® (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity. It was the first medication ever approved for OSA. It is not approved for mild OSA, and it is not approved for patients with OSA who do not have obesity. Approval was based on the SURMOUNT-OSA phase 3 trials, which showed up to a 62.8% reduction in apnea-hypopnea index versus placebo.

Do not stop or reduce CPAP without consulting your sleep physician. CPAP remains the gold standard for moderate-to-severe OSA and provides immediate benefit from the first night of use. Tirzepatide works gradually through weight reduction. The two are considered complementary, not interchangeable — SURMOUNT-OSA specifically included a trial arm of patients who remained on PAP therapy throughout. Any change to PAP therapy should follow a repeat sleep study and a clinical decision by your sleep specialist.

Weight reduction can meaningfully reduce OSA severity for many patients, but “cure” overstates it. Approximately 60% of moderate-to-severe OSA cases are attributable to obesity — meaning 40% are not. A 2025 meta-analysis found that most adults with OSA do not have obesity: 44.4% have overweight status and 23.5% have normal weight or below. Anatomical factors, age, and sex contribute independently. Weight loss is a powerful lever for many patients, but OSA severity should always be reassessed with a repeat sleep study rather than assumed to have resolved.

Diagnosis requires a sleep study — either an in-lab polysomnogram or an approved home sleep apnea test, both ordered by a physician. Common signs worth raising with a clinician include loud snoring, witnessed pauses in breathing during sleep, waking unrefreshed, daytime sleepiness, morning headaches, and difficulty concentrating. Snoring alone is not diagnostic — while 94% of people with OSA snore, most people who snore do not have OSA. If you suspect sleep apnea, speak to your primary care provider or a board-certified sleep medicine physician about testing.

More Research

Explore the Full GoalBMI Statistics Library

📊 All 2026 Statistics Reports

GLP-1 Weight Loss Statistics 2026 Semaglutide Statistics 2026 — Ozempic® & Wegovy® Data Tirzepatide Statistics 2026 — Zepbound® & Mounjaro® Data Obesity Statistics in America 2026 Type 2 Diabetes Statistics 2026 Telehealth Weight Loss Statistics 2026 GLP-1 Insurance Coverage Statistics 2026 GLP-1 Side Effects Statistics 2026

References

Sources & Medical References

1Malhotra A., Grunstein R.R., Fietze I., et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). NEJM 391(13), 1193–1205. nejm.org
2U.S. Food and Drug Administration (December 20, 2024). FDA approves first medication for obstructive sleep apnea. fda.gov
3SLEEP / Oxford Academic (2025). Unmasking Obstructive Sleep Apnea: Estimated Prevalence and Impact in the United States. 80.6M adults, 32.2% prevalence. academic.oup.com
4SLEEP / Oxford Academic (2025). Prevalence and Unmet Need of Obstructive Sleep Apnea in the United States. 80% undiagnosed, treatment funnel data. academic.oup.com
5American Academy of Sleep Medicine / Frost & Sullivan. Economic burden of undiagnosed sleep apnea in the U.S. is nearly $150B per year. aasm.org
6NIH PMC (2025). The relationship between obesity and obstructive sleep apnea in four community-based cohorts: IPD meta-analysis of 12,860 adults. ncbi.nlm.nih.gov
7Boers E., Barrett M., Benjafield V. (August 2025). Projecting the 30-year burden of obstructive sleep apnoea in the USA: a prospective modelling study. Lancet Respir Med. pubmed.ncbi.nlm.nih.gov
8Baser O., et al. (January 2025). Tirzepatide and Semaglutide for the Treatment of Obstructive Sleep Apnea and Obesity: A Retrospective Analysis. Medical Research Archives 13(1). esmed.org
9ResMed (2026). FAQ: Anti-Obesity Medications and Obstructive Sleep Apnea. Clinical guidance on GLP-1s alongside PAP therapy. resmed.com
10Faria A., et al. (2021). The public health burden of obstructive sleep apnea. Sleep Science. Motor vehicle collision and healthcare cost data. ncbi.nlm.nih.gov
11PRO-CON OSA Survey (2025). Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea: Patient and Provider Preferences for CPAP and/or Tirzepatide. UCSD / medRxiv. medrxiv.org
12American Academy of Sleep Medicine (2026). Zepbound® (tirzepatide) for Obstructive Sleep Apnea — provider fact sheet. aasm.org

Medically Reviewed by Karla K. Mioduchoski, FNP-BC

Board-Certified Family Nurse Practitioner — GoalBMI Wellness

Karla K. Mioduchoski, FNP-BC is a board-certified Family Nurse Practitioner providing physician-supervised medical weight loss, GLP-1 support, peptide therapy, and telehealth wellness care through GoalBMI Wellness. All statistical data in this article was reviewed for clinical accuracy in July 2026.

Medical Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Obstructive sleep apnea cannot be diagnosed without a sleep study ordered by a physician. Zepbound® (tirzepatide) is FDA-approved for moderate-to-severe OSA only in adults with obesity, in combination with a reduced-calorie diet and increased physical activity — it is not approved for mild OSA or for patients without obesity. Medication is not a substitute for CPAP or other positive airway pressure therapy; never stop or change PAP therapy without consulting your sleep physician. All treatment decisions require evaluation by a licensed healthcare provider. In a medical emergency, call 911.

Get Started

Book an appointment and take the first step toward better health.

Book Now

Related Weight Loss Programs